Results 11,141-11,160 of 12,718 for speaker:Louise O'Reilly
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: We are going down the road of being very specific about one drug in this regard.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: Will Professor Barry respond to that? Then we can move on to getting answers to the other questions that were asked.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: I am conscious that questions from Deputy Brassil and Senator Swanick have not been answered yet. The witnesses might address those, please.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: Mr. Hennessy was asked for a date. He said that the process was in the final stages. What does that mean?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: I am in the final stages of renovating a house, and my view on how long that will be is very different from what the people who are building it believe it will be. How long is a piece of string? If the process is in the final stages, are we talking days, weeks or months and will Mr. Hennessy give us a date?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: I thank Mr. Hennessy.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: Deputy O'Connell will ask the quickest question in the world. Two other members have indicated.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: We can revert to that.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: I thank the Deputy, who said that she would be brief. Senator Mullen asked a question, so the witnesses might address it. Three more members have indicated and will be taken next. The witnesses might keep their answers brief, but specific.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: I must remind Senator Mullen that I am conscious there are people-----
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: Can I ask the witnesses to keep their responses as brief as they can because I am conscious that there are very patient committee members also waiting to come in?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: I thank Senator Dolan and Deputies Murphy and Durkan for their patience.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: I invite Deputy Durkan, the master of brevity.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: I have no doubt.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: Obviously, any decisions taken by the committee will not be taken in public, as is the custom. Will the witnesses respond to the questions? Banking questions is not ideal so could witnesses go through them? Members reserve the right to come if anything is missed.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: I apologise for interrupting, but the point was made on the benefit of keeping people out of hospital. When we speak about the nine drugs awaiting approval, has this been factored in by the HSE?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: When we say those nine drugs would cost €120 million over five years-----
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: Apologies for the interruption.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: To be very clear on this, as a layperson it strikes me that science is science and tests are tests, so I share Deputy Durkan's surprise there are not standards throughout the European Union by which these things can be assessed. When a purely scientific analysis is done on outcomes, a person is a person and it does not matter whether he or she is in Lithuania, Azerbaijan or Dublin.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Louise O'Reilly: The Deputy's point is well made. We will move on.